Prostate Cancer
Conditions
Brief summary
This is a pilot exercise physiology and quality of life study of subjects receiving standard of care therapy for their prostate cancer using FDA-approved drugs per their labeling (abiraterone, enzalutamide, or sipuleucel-T). Subjects with progressive, asymptomatic or minimally symptomatic mCRPC scheduled to be treated with either enzalutamide or abiraterone acetate for ≥3 months or a course of sipuleucel-T will be allocated to one of the treatments arms, according to the treatment chosen by the treating physician.
Interventions
DRUGEnzalutamide
DRUGAbiraterone acetate
DRUGSipuleucel-T
Sponsors
Duke University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male age ≥ 18 years 2. Histologically-confirmed adenocarcinoma of the prostate 3. Surgically or medically castrated 4. Starting either enzalutamide or abiraterone for at least 12 weeks OR starting a course of sipuleucel-T. Subjects being treated concomitantly with abiraterone or enzalutamide plus sipuleucel-T are eligible and should be enrolled on Arm A or Arm B, as appropriate. 5. ECOG performance status 0 or 1 6. Able to read and understand English, in the opinion of the treating provider, well enough to complete the study questionnaires 7. Able to comply with study requirements 8. Successful completion of a CPET in the opinion on the investigator
Exclusion criteria
1. Subjects who have had any surgical procedure (i.e. TURP, etc.) within 4 weeks prior to entering the study. 2. Subjects receiving treatment with BOTH abiraterone and enzalutamide 3. For Arm C (sipuleucel-T) only: 1. subjects receiving abiraterone or enzalutamide concomitantly with sipuleucel-T should only be enrolled on Arm A or Arm B, as appropriate. 2. subjects who have received prior sipuleucel-T 4. Subjects who are receiving any other investigational agents (i.e. enzalutamide or abiraterone plus an investigational drug). 5. Subjects with any of the following absolute contraindications to maximal exercise testing as recommended by the American Thoracic Society and the exercise testing guidelines for cancer subjects, in the opinion of the treating provider: (a) acute myocardial infarction (3-5 days), (b) unstable angina, (c) uncontrolled arrhythmias causing symptoms or hemodynamic compromise, (d) syncope, (e) acute endocarditis, (f) acute myocarditis or pericarditis, (g) uncontrolled heart failure, (h) acute pulmonary embolus or pulmonary infarction, (i) thrombosis of lower extremities, (j) suspected dissecting aneurysm, (k) uncontrolled asthma, (l) pulmonary edema, (m) room air desaturation at rest \<85%, (n) respiratory failure, (o) acute noncardiopulmonary disorder that may affect exercise performance or be aggravated by exercise, (p) mental impairment leading to inability to cooperate, and (q) extensive bone metastases. 6. Significant cardiovascular disease, including: 1. Symptomatic left ventricular dysfunction or known baseline left ventricular ejection fraction (LVEF) by multigated acquisition scan (MUGA) or echocardiogram (ECHO) of \< lower limit of institutional normal (LLN). Symptomatic is defined as New York Heart Association (NYHA) Class II or greater. Note: MUGA and ECHCO do NOT need to be measured to establish eligibility for this study. 2. Uncontrolled hypertension 3. Myocardial infarction, severe angina, or unstable angina within 6 months prior to administration of first dose of study drug 4. History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation) within 12 months of first dose of study drug 5. Uncontrolled cardiac arrhythmias 6. Coronary or peripheral artery bypass graft within 6 months of first dose of study drug 7. History of CVA, TIA, or rest claudication within 6 months of first dose of study drug 7. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements 8. Known or suspected brain metastasis or leptomeningeal disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in VO2peak from baseline with abiraterone, enzalutamide or sipuleucel-T at week 21 | baseline, 21 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Compare VO2peak with patient- and physician reported functional status | 21 weeks |
| Evaluate the variability of CPET in all arms | 2 weeks |
Countries
United States
Outcome results
None listed